Last reviewed: May 14, 2026

Last updated: May 14, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide patches remain investigational and are not yet FDA-approved for weight management, while injectable semaglutide has robust clinical evidence supporting its efficacy. This distinction matters because delivery method, formulation, and individual biomarkers all influence treatment outcomes and tolerability.

Choosing between available semaglutide options requires understanding what clinical data supports each approach and how your genetic background may relate to medication response. PlexusDx focuses on precision wellness by helping you evaluate options with both evidence and personalized insight.

Current Status of Semaglutide Delivery Systems

Transdermal semaglutide patches are in clinical development but not yet approved by the FDA for any indication. Injectable semaglutide (subcutaneous weekly or compounded formulations) has demonstrated consistent weight loss results in randomized trials, with participants losing 10-15% of body weight over 68 weeks in landmark GLP-1 receptor agonist studies.

The patch format appeals to patients seeking needle-free options, but investigational status means limited safety and efficacy data compared to injections. PlexusDx partners with licensed 503A compounding pharmacies to provide injectable semaglutide at transparent pricing, ensuring access to evidence-supported formulations.

Clinical Evidence: How Injectable and Transdermal Routes Compare

Injectable semaglutide has undergone extensive Phase III trials with clear dose-response relationships and safety profiles. Transdermal delivery for semaglutide is still being studied, with preliminary data suggesting potential bioavailability challenges and variable absorption through skin barriers.

Delivery Method Approval Status Clinical Evidence Level Typical Efficacy Range
Injectable Semaglutide FDA-approved (brand and compounded) High (Phase III RCTs) 10-15% weight loss
Transdermal Patch Investigational only Limited (early-phase studies) Data pending
Oral Semaglutide FDA-approved High (Phase III RCTs) 7-12% weight loss
Compounded Injectable 503A pharmacy-prepared Supported by reference standard 10-15% weight loss

Bioavailability and Individual Response Factors

Injectable semaglutide achieves predictable pharmacokinetics with subcutaneous administration, bypassing first-pass metabolism. Individual response varies based on factors including body composition, GLP-1 receptor genetics, and metabolic state—not delivery method alone.

Transdermal patches must overcome skin barrier resistance to achieve therapeutic levels. Genetic variants in the GLP1R gene may influence how effectively your body responds to semaglutide regardless of delivery route, making personalized assessment valuable before committing to a specific formulation.

Safety Considerations and Provider Decision Framework

Injectable semaglutide has established adverse event profiles: nausea (25-60%), vomiting, diarrhea, and rare reports of pancreatitis or thyroid concerns. Transdermal formulations may present different safety profiles pending completion of clinical trials. Medical supervision is essential for any GLP-1 therapy.

Before selecting a delivery method, discuss with your provider your gastrointestinal tolerance, needle anxiety, skin sensitivity, and medication history. Compounded injectable options from 503A pharmacies offer cost-effective access to evidence-supported dosing under licensed pharmacy oversight and provider guidance.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test analyzes variants in GLP1R (rs6923761) and GIPR (rs1800437) pathways, which may help provide context about your genetic predisposition to GLP-1 receptor sensitivity. This information should be interpreted with your qualified healthcare provider to inform which delivery method and dosing strategy may align with your physiology.

Genetic predisposition does not predict exact medication response, but certain variants may correlate with differential GLP-1 efficacy across populations. The Precision Peptide test reveals your individual status in these peptide pathway genes, supporting a more personalized conversation about whether injectable semaglutide, oral formulations, or combination approaches might suit your baseline.

Understanding your genetic context alongside clinical evidence helps your provider tailor treatment selection. PlexusDx offers the Precision Peptide Genetic Test as a $99 add-on or $298 standalone to support this informed decision-making before starting any GLP-1 therapy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is the semaglutide patch available for weight loss right now?

No. Semaglutide patches are still investigational and not yet FDA-approved. Injectable semaglutide and oral formulations are currently available through licensed pharmacies and compounding services approved by your healthcare provider.

Do transdermal patches work as well as injections for weight loss?

Clinical evidence is limited for transdermal semaglutide. Injectable and oral semaglutide have demonstrated 7-15% weight loss in large randomized trials. Until patch studies are complete, injections remain the evidence-backed delivery method.

What does PlexusDx offer for semaglutide treatment?

PlexusDx provides compounded semaglutide injections from licensed 503A pharmacies at $149/mo, plus oral semaglutide starting at $249/mo. The Precision Peptide Genetic Test ($99 add-on or $298 standalone) can inform your treatment selection with your provider.

What are the most common side effects of semaglutide injections?

Nausea (25-60%), vomiting, diarrhea, and constipation are typical. Most resolve over weeks. Rare serious effects include pancreatitis signs. Your provider should monitor for any concerning symptoms and adjust dosing accordingly.

Can genetic testing help me decide between semaglutide delivery methods?

The Precision Peptide Genetic Test reveals your GLP1R and GIPR pathway predispositions, which may provide context for how your body might respond to GLP-1 therapy. This should be discussed with your provider as part of personalized treatment planning.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves